THE WIRE · № 61514
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
01 THE MACHINE READ
WHY IT MATTERS.
Preclinical obesity data from a small HKEX-listed biotech; no revenue or approval path yet, so read-through to large-cap obesity names is minimal.
Early obesity pipeline news, not investable yet
Peer-reviewed data or clinical trial start
Preclinical results may not translate to humans
FULL DISPATCH
HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt2026-10-02 09:41 UTC
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy2026-10-02 10:00 UTC
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 20262026-10-02 11:00 UTC
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals2026-10-02 11:18 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 10:57 UTC
Afya (AFYA) Stock Looks Cheap Following A Fresh Merger Agreement2026-10-02 11:45 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.